Drug intelligence / Profile preview

Buventol Easyhaler

Development stage
Phase 4
Lead developer
Orion
Modality
Small Molecules
Administration
Inhalation
01

Overview

Buventol Easyhaler is a branded dry powder inhaler formulation of salbutamol (albuterol) sulfate, a short-acting selective beta2-adrenergic receptor agonist used as a rapid-acting bronchodilator for the relief and prevention of acute bronchospasm in asthma, exercise-induced bronchospasm, and chronic obstructive pulmonary disease with reversible airway obstruction.[1][7][17] By selectively stimulating beta2 receptors in bronchial smooth muscle, salbutamol activates adenylyl cyclase, increases intracellular cAMP, and promotes relaxation of airway smooth muscle, leading to prompt bronchodilation within minutes and a duration of action of about 4–6 hours.[1][2] Buventol Easyhaler is intended as a “reliever” or rescue medication rather than long-term controller therapy, and is marketed in multiple regions by Orion and its partners for on-demand symptomatic treatment and prophylaxis before exercise.[1][5][8][11][13][17]

Brand names
BuventolBuventol Easyhaler
Other names
salbutamol sulfatesalbutamol Orion
02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on Buventol Easyhaler.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buventol Easyhaler.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call